| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C17H27ClN2O |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Ropivacaine hydrochloride potently blocks sodium channels, interrupting impulse conduction through reversible inhibition of sodium ion influx in nerve fibers[1][2]. It also inhibits the two-pore domain potassium channel K2P TREK-1, with an IC50 of 402.7 μM in COS-7 cell membranes[3]. In vivo, it has been used for managing neuropathic pain[1]. It is supplied as a white to off-white solid (C17H27ClN2O, MW 310.86) at 99.49% purity.
Physical & Chemical Properties
| CAS Number | 98717-15-8 |
|---|---|
| Molecular Formula | C17H27ClN2O |
| Molecular Weight | 310.86 g/mol |
| Purity | 99.49% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | [H]Cl.O=C([C@H]1N(CCC)CCCC1)NC2=C(C)C=CC=C2C |
| Signaling Pathway | Membrane Transporter/Ion Channel |
| Solubility | In Vitro: DMSO: 10 mg/mL (32.17 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O: 10 mg/mL (32.17 mM; Requires sonication) |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
IC50: sodium ion influx[1] IC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)[3]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 10 mg/mL (32.17 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
| H2O | 10 mg/mL (32.17 mM) | requires sonication |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 1 mg/mL (3.22 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 1 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (10.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 1 mg/mL (3.22 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 1 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (10.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 1 mg/mL (3.22 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 1 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (10.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vivo
Epidural Ropivacaine hydrochloride effectively blocks neuropathic pain, covering both mechanical allodynia and heat hyperalgesia, without inducing analgesic tolerance, and significantly delays the onset of neuropathic pain caused by peripheral nerve injury[1]. Ropivacaine hydrochloride inhibits the pressure-induced increase in filtration coefficient (Kf) with no effect on pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), or zonal characteristics (ZC)[2]. Ropivacaine hydrochloride prevents pressure-induced lung edema and the associated hyperpermeability, as shown by PaO2, lung wet-to-dry ratio and plasma volume kept at levels similar to those of sham rats[2]. Ropivacaine hydrochloride blocks pressure-induced NO production, as shown by lower lung nitro-tyrosine content than in hypertensive lungs[2].
| Animal Model | Adult Sprague-Dawley rats (300–400g)[2] |
|---|---|
| Dosage | 1 μM |
| Administration | Infusion (added to the perfusate reservoir) |
| Result | Attenuated pressure-dependent increases in filtration coefficient (Kf). |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer. J Exp Clin Cancer Res 2024 Mar 25;43(1):90. PMID: 38523299
Local anesthetics impair the growth and self-renewal of glioblastoma stem cells by inhibiting ZDHHC15-mediated GP130 palmitoylation. Stem Cell Res Ther 2021 Feb 4;12(1):107. PMID: 33541421
Exploring the mechanism of ropivacaine in alleviating neuropathic pain via the mTOR-PKM2/STAT3-H4K12 lactylation axis. Int Immunopharmacol 2026 May 14:182:116838. PMID: 42134294
Mechanism of the AMPK/SIRT1 pathway in gut dysbiosis-mediated postoperative cognitive dysfunction in aged mice. Int J Neuropsychopharmacol 2025 Oct 1;28(10):pyaf066. PMID: 41031618
Effect of species, concentration and volume of local anesthetics on intervertebral disk degeneration in rats with discoblock. Eur Spine J 2022 Nov;31(11):2960-2971. PMID: 36152221
KCNK2-mediated regulation of MMP-2/9 by PlGF influences uterine artery function in pregnancy-induced hypertension. BMC Pregnancy Childbirth 2025 Jun 2;25(1):646. PMID: 40457264
Inhibition of FOXO3 ameliorates ropivacaine-induced nerve cell damage through the miR-126-5p/TRAF6 axis. In Vitro Cell Dev Biol Anim 2024 Oct;60(9):1109-1120. PMID: 39227495
Dexmedetomidine protects against Ropivacaine-induced neuronal pyroptosis via the Nrf2/HO-1 pathway. J Toxicol Sci 2023;48(3):139-148. PMID: 36858639
